Unknown

Dataset Information

0

Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.


ABSTRACT:

Background

We previously demonstrated that nuclear and cytoplasmic accumulation of the intracellular domain (Ep-ICD) of epithelial cell adhesion molecule (EpCAM) accompanied by a reciprocal reduction of its extracellular domain (EpEx), occurs in aggressive thyroid cancers. This study was designed to determine whether similar accumulation of Ep-ICD is a common event in other epithelial cancers.

Methodology and results

Ten epithelial cancers were immunohistochemically analyzed using Ep-ICD and EpEx domain-specific antibodies. The subcellular localization of EpEx and Ep-ICD in the human colon adenocarcinoma cell line CX-1 was observed using immunofluorescence. Nuclear and cytoplasmic Ep-ICD expression was increased in cancers of the breast (31 of 38 tissues, 82%), prostate (40 of 49 tissues, 82%), head and neck (37 of 57 tissues, 65%) and esophagus (17 of 46 tissues, 37%) compared to their corresponding normal tissues that showed membrane localization of the protein. Importantly, Ep-ICD was not detected in the nuclei of epithelial cells in most normal tissues. High nuclear and cytoplasmic Ep-ICD accumulation also occurred in the other six epithelial cancer types analyzed - lung, colon, liver, bladder, pancreatic, and ovarian. A concomitant reduction in membrane EpEx expression was observed in a subset of all cancer types. Receiver operating characteristic curve analysis revealed nuclear Ep-ICD distinguished breast cancers with 82% sensitivity and 100% specificity and prostate cancers with 82% sensitivity and 78% specificity. Similar findings were observed for cytoplasmic accumulation of Ep-ICD in these cancers. We provide clinical evidence of increased nuclear and cytoplasmic Ep-ICD accumulation and a reduction in membranous EpEx in these cancers.

Conclusions

Increased nuclear and cytoplasmic Ep-ICD was observed in all epithelial cancers analyzed and distinguished them from normal tissues with high-sensitivity, specificity, and AUC. Development of a robust high throughput assay for Ep-ICD will facilitate the determination of its diagnostic, prognostic and therapeutic relevance in epithelial cancers.

SUBMITTER: Ralhan R 

PROVIDER: S-EPMC2994724 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>We previously demonstrated that nuclear and cytoplasmic accumulation of the intracellular domain (Ep-ICD) of epithelial cell adhesion molecule (EpCAM) accompanied by a reciprocal reduction of its extracellular domain (EpEx), occurs in aggressive thyroid cancers. This study was designed to determine whether similar accumulation of Ep-ICD is a common event in other epithelial cancers.<h4>Methodology and results</h4>Ten epithelial cancers were immunohistochemically analyzed using  ...[more]

Similar Datasets

| S-EPMC4335027 | biostudies-literature
| S-EPMC2838813 | biostudies-literature
2016-07-13 | GSE84304 | GEO
| S-EPMC4219162 | biostudies-literature
| S-EPMC3159454 | biostudies-literature
| S-EPMC7514872 | biostudies-literature
| S-EPMC4878613 | biostudies-literature
| S-EPMC5417308 | biostudies-literature
| S-EPMC3502349 | biostudies-literature
| S-EPMC3458930 | biostudies-literature